内容紹介
Summary
Background: Ramucirumab, an antiangiogenic agent, often causes proteinuria as a characteristic adverse effect. We retrospectively evaluated proteinuria and clarified the significance of the protein/creatinine ratio by using single urine samples from patients with advanced gastric cancer who were treated with ramucirumab. Methods: Twenty-three patients who received ramucirumab between June 2015 and April 2016 were enrolled. A total of 199 urinalysis specimens were qualitatively analyzed to obtain urine protein levels and the protein/creatinine ratio, and the values were compared. Results: Frequency of proteinuria was 43.5%(grade 1: 26.1%, grade 2: 8.7%, and grade 3: 8.7%). The protein/creatinine ratio was less than 2 in-, ±, and 1+ based on the urine protein qualitative examination; 12.5% of 2+and 71.4% of 3+or 4+had a protein/creatinine ratio over 2. Conclusions: In patients with gastric cancer, treated with ramucirumab, the protein/creatinine ratio should be examined in cases of 2+, 3+or 4+via a qualitative examination.
要旨
血管新生阻害剤であるramucirumab(RAM)の特徴的な有害事象に蛋白尿がある。今回,尿中蛋白/クレアチニン比(uP/C)の測定意義を明らかにするため後方視的に検討した。RAMを投与された進行再発胃癌23例,延べ199回の尿検査検体を対象とし,蛋白尿の発現頻度とその程度を調査し,尿蛋白定性検査(uPr)とuP/Cを比較した。 蛋白尿の発現は,43.5%(grade 2: 8.7%,grade 3: 8.7%)であった。uPr(-～1+)はすべてuP/C<2で,uPr(2+)の12.5%,uPr(3+～4+)の71.4%はuP/C≧2であった。uPrで2+以上では,uP/Cの測定が重要である。
目次
Background: Ramucirumab, an antiangiogenic agent, often causes proteinuria as a characteristic adverse effect. We retrospectively evaluated proteinuria and clarified the significance of the protein/creatinine ratio by using single urine samples from patients with advanced gastric cancer who were treated with ramucirumab. Methods: Twenty-three patients who received ramucirumab between June 2015 and April 2016 were enrolled. A total of 199 urinalysis specimens were qualitatively analyzed to obtain urine protein levels and the protein/creatinine ratio, and the values were compared. Results: Frequency of proteinuria was 43.5%(grade 1: 26.1%, grade 2: 8.7%, and grade 3: 8.7%). The protein/creatinine ratio was less than 2 in-, ±, and 1+ based on the urine protein qualitative examination; 12.5% of 2+and 71.4% of 3+or 4+had a protein/creatinine ratio over 2. Conclusions: In patients with gastric cancer, treated with ramucirumab, the protein/creatinine ratio should be examined in cases of 2+, 3+or 4+via a qualitative examination.
要旨
血管新生阻害剤であるramucirumab(RAM)の特徴的な有害事象に蛋白尿がある。今回,尿中蛋白/クレアチニン比(uP/C)の測定意義を明らかにするため後方視的に検討した。RAMを投与された進行再発胃癌23例,延べ199回の尿検査検体を対象とし,蛋白尿の発現頻度とその程度を調査し,尿蛋白定性検査(uPr)とuP/Cを比較した。 蛋白尿の発現は,43.5%(grade 2: 8.7%,grade 3: 8.7%)であった。uPr(-～1+)はすべてuP/C<2で,uPr(2+)の12.5%,uPr(3+～4+)の71.4%はuP/C≧2であった。uPrで2+以上では,uP/Cの測定が重要である。